Avatrombopag, also known as AKR-501, YM477, AS 1670542 or E5501, is a novel orally-active thrombopoietin (TPO) receptor agonist. AKR-501 specifically targeted the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as rhTPO did. AKR-501 may be useful in the treatment of patients with thrombocytopenia.
Miao, Dezu; Hu, Qingwen; Cong, Chao; Cao, Yan; Yu, Zhibo; Wang, Hongguang. Preparation method of platelet increasing agent Avatrombopag. Assignee Reyoung Pharmaceutical Co., Ltd., Peop. Rep. China. CN 107383000. (2017).
